Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-06-07
2005-06-07
McKenzie, Thomas C. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S310000, C514S313000, C514S323000, C514S363000, C514S367000, C514S370000, C514S371000, C514S372000, C514S380000, C514S397000, C514S419000, C546S143000, C546S162000, C546S201000, C548S139000, C548S159000, C548S195000, C548S212000, C548S245000, C548S246000, C548S312100, C548S454000, C548S493000
Reexamination Certificate
active
06903104
ABSTRACT:
The invention is based on the discovery that certain 3-oxoacetamideindolyl compounds have potent anticancer and anti-angiogenic activity. The 3-oxoacetamideindolyl compounds are of the following formula.In this formula, each R1is independently isoxazolyl, thiazolyl, isothiazolyl, 1,3,4-thiadiazolyl, 1,3-benzothiazolyl, quinolyl, isoquinolyl, thionaphthenyl, or benzofuranyl, each being optionally substituted with 1-6 independent R5; or when taken together with R2and the nitrogen atom to which they are attached form a 5-8 membered ring comprising C, N, S, or O atoms wherein any atom is optionally substituted with an independent R5. Each R2is independently H, C1-C10 alkyl, or aryl, each being optionally substituted with 1-4 independent R5; or when taken together with R1and the nitrogen atom to which they are attached form a 5-8 membered ring comprising C, N, S, or O atoms wherein any atom is optionally substituted with an independent R5. Each R3is independently C3-C10 cycloalkyl, C4-C10 cycloalkenyl, isoxazolyl, furanyl, thiophenyl, thiazolyl, imidazolyl, pyridyl, or heterocyclyl, each being optionally substituted with 1-4 independent R5. Each R4is independently H, NO2, halo, CN, R7, OR7, CO2R7, SR7, NR7R7, C(O)R7, C(O)NR7R7, OC(O)R7, S(O)2R7, S(O)2NR7R7, NR7C(O)NR7R7, NR7C(O)R7, NR7(COOR7), NR7S(O)2NR7R7, NR7S(O)2R7, or S(O)2OR7.
REFERENCES:
patent: 2825734 (1958-03-01), Speeter
patent: 3351630 (1967-11-01), Shen
patent: 6008231 (1999-12-01), Lebaut et al.
patent: 6114355 (2000-09-01), D'Amato
patent: 6232327 (2001-05-01), Nickel et al.
patent: 6251923 (2001-06-01), Hofgen et al.
patent: 6469006 (2002-10-01), Blair et al.
patent: 6613794 (2003-09-01), Hofgen et al.
patent: 198 18 964 (1999-11-01), None
patent: 0 675 110 (1995-10-01), None
patent: 1028812 (1966-05-01), None
patent: 57006878 (1982-01-01), None
patent: 6502481 (1965-02-01), None
patent: WO 99/51224 (1999-10-01), None
patent: WO 02/08225 (2002-01-01), None
patent: WO 03/022280 (2003-03-01), None
Draetta, G. and Pagano, M. in “Annual Reports in Medicinal Chemistry, vol. 31”, 1996, Academic Press, San Diego, p 241-246.
Brown JM, Oncol Res. 1997;9(5):213-5.
Weinstein JN, et al, Science. Jan. 17, 1997;275(5298):343-9.
Hamburger, Anne W., JNCI, 66 (6), 1981, pp. 981-986.
Patterson, A. M. et al, “The Ring Index, 2ndEd.”, American Chemical Society, Columbus, OH, 1960, entry #2527, p. 326.
Chen Chiung-Tong
Chen Shu-Jen
Hsu Ming-Chu
Hwang Der-Ren
Li Wen-Tai
Fish & Richardson P.C.
McKenzie Thomas C.
National Health Research Institutes
LandOfFree
Indol-3-YL-2-oxoacetamide compounds and methods of use thereof does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Indol-3-YL-2-oxoacetamide compounds and methods of use thereof, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indol-3-YL-2-oxoacetamide compounds and methods of use thereof will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3463362